Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
An oral synthetic retinoid, which according to some dermatologists will revolutionize treatment for severe cystic acne, is likely to be available for general clinical use later this year. Isotretinoin 13-cis-retinoic acid) has been recommended for approval by the Food and Drug Administration pending some labeling changes by its manufacturer, Hoffman-La Roche Inc, Nutley, NJ. About one third of the university dermatology centers in the United States have conducted clinical trials with one of several synthetic retinoids, and isotretinoin appears to be the most effective for treating cystic acne, according to Carl Ehmann, MD, director of clinical research for dermatology at Hoffman-La Roche. Isotretinoin has an impressive track record so far: At doses ranging from 0.02 to 2.0 mg/kg/day, dermatologists from the United States and several European countries report that virtually all patients experience complete amelioration of their acne, usually after an eight- to 16-week course of treatment. In
JAMA – American Medical Association
Published: Apr 2, 1982
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.